Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedaplatin and Capecitabine in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03503136Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2018
- Primary completion
- Jun 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nedaplatin, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
nedaplatincapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03503136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503136.